Active Biotech AB publ
F:BTPC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Active Biotech AB publ
F:BTPC
|
SE |
|
J
|
Johnson Controls International PLC
F:TYIA
|
IE |
|
Bilibili Inc
NASDAQ:BILI
|
CN |
|
PSP Swiss Property AG
F:P7S
|
CH |
|
Knight-Swift Transportation Holdings Inc
NYSE:KNX
|
US |
|
H
|
Huron Consulting Group Inc
F:HUR
|
US |
|
E
|
ESR Cayman Ltd
HKEX:1821
|
HK |
|
Italian Exhibition Group SpA
MIL:IEG
|
IT |
|
I
|
Industrie De Nora SpA
MIL:DNR
|
IT |
|
S
|
Siam Wellness Group PCL
SET:SPA
|
TH |
|
Metso Outotec Corp
OTC:OUKPY
|
FI |
|
Acuren Corp
NYSE:TIC
|
US |
|
O
|
Overstock.com Inc
F:OVER
|
US |
Active Biotech AB publ
Active Biotech is a Swedish biotech company that develops drug candidates for diseases such as cancer, inflammatory disorders, and autoimmune conditions. It does not run a big drug-manufacturing business; instead, it focuses on discovering molecules, testing them in clinical trials, and advancing the most promising programs toward approval. Its work is aimed at finding treatments that can be licensed to larger drug companies or taken forward with partners. The company makes money mainly through collaboration deals, licensing agreements, and potential milestone or royalty payments tied to successful drug development and future sales. Its main counterparts are pharmaceutical partners, research institutions, and eventually healthcare systems and patients if a drug reaches the market. Because biotech development is expensive and risky, this business model depends heavily on finding the right scientific targets and building partnerships that can share the cost and reward. What makes Active Biotech different is that it sits early in the drug value chain, before most of the commercial work begins. That means its value comes from scientific assets and development expertise rather than from selling products itself. For investors, it is best understood as a research-driven drug developer whose outcomes depend on the progress of a small number of pipeline programs.
Active Biotech is a Swedish biotech company that develops drug candidates for diseases such as cancer, inflammatory disorders, and autoimmune conditions. It does not run a big drug-manufacturing business; instead, it focuses on discovering molecules, testing them in clinical trials, and advancing the most promising programs toward approval. Its work is aimed at finding treatments that can be licensed to larger drug companies or taken forward with partners.
The company makes money mainly through collaboration deals, licensing agreements, and potential milestone or royalty payments tied to successful drug development and future sales. Its main counterparts are pharmaceutical partners, research institutions, and eventually healthcare systems and patients if a drug reaches the market. Because biotech development is expensive and risky, this business model depends heavily on finding the right scientific targets and building partnerships that can share the cost and reward.
What makes Active Biotech different is that it sits early in the drug value chain, before most of the commercial work begins. That means its value comes from scientific assets and development expertise rather than from selling products itself. For investors, it is best understood as a research-driven drug developer whose outcomes depend on the progress of a small number of pipeline programs.
